{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:20:05Z","timestamp":1789194005497,"version":"build-2803163510"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Iatrogenic immune-mediated inflammatory disorders of the spinal cord are an uncommon but potentially severe complication of drug therapy for several human diseases. Particularly the introduction of novel biological agents in the treatment of systemic inflammatory disorders and cancer immunotherapy have led to a significant increase in immune-related adverse events of the central nervous system (CNS). The use of Tumor necrosis factor alpha (TNF-alpha) inhibitors in rheumatic and inflammatory bowel diseases has been associated with demyelinating and other inflammatory CNS conditions, including myelitis. The introduction of immune checkpoint inhibitors in the treatment of several human malignancies has led to an increase in drug-induced immune-related adverse events including in the CNS. Other drugs that have been associated with immune-mediated myelitis include tyrosine-kinase inhibitors and chimeric antigen receptor (CAR) T Cell therapy. A high degree of suspicion is necessary when diagnosing these conditions, as early diagnosis and treatment is crucial in preventing further neurological damage and disability. The treatment of drug-induced inflammatory myelitis typically involves administration of high-dose intravenous corticosteroids, however additional immunosuppressive agents may be required in severe or refractory cases. While most cases are monophasic and remit following discontinuation of the offending agent, chronic immunosuppressive therapy may be indicated in cases with a progressive or relapsing disease course or when a diagnosis of a specific underlying neuro-inflammatory disorder is made. Outcomes are generally favorable, however depend on the specific therapeutic agent used, the clinical presentation and patient factors. In this review we aim to describe the clinical characteristics, imaging findings and management for the most common forms of iatrogenic immune-mediated myelopathies.<\/jats:p>","DOI":"10.3389\/fneur.2022.1003270","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T08:57:05Z","timestamp":1664441825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-related immune-mediated myelopathies"],"prefix":"10.3389","volume":"13","author":[{"given":"David","family":"Gritsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Valencia-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/nop\/npy039","article-title":"Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors","volume":"6","author":"Anderson","year":"2018","journal-title":"Neurooncol Pract."},{"key":"B2","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.155.10.4521","article-title":"CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system","volume":"155","author":"Khoury","year":"1995","journal-title":"J Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/WCO.0b013e3283398c96","article-title":"Demyelination as a complication of new immunomodulatory treatments","volume":"23","author":"Lysandropoulos","year":"2010","journal-title":"Curr Opin Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2017.09.026","article-title":"Immune checkpoint inhibitor\u2013associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis?","volume":"87","author":"Strik","year":"2017","journal-title":"Eur J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"538695","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.pharep.2014.05.004","article-title":"TNF inhibitors\u2013mechanisms of action, approved and off-label indications","volume":"66","author":"Cessak","year":"2014","journal-title":"Pharmacol Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1097\/MIB.0000000000000533","article-title":"New insights into the mechanisms of action of anti\u2013tumor necrosis factor-\u03b1 monoclonal antibodies in inflammatory bowel disease","volume":"21","author":"Slevin","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult Scler."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten Barkhof","year":"1996","journal-title":"Neurology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS Demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","article-title":"Tumor necrosis factor alpha (TNF-\u03b1), anti-TNF-\u03b1 and demyelination revisited: an ongoing story","volume":"234","author":"Caminero","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/1876894601002010160","article-title":"TNF-\u03b1: a paradigm of paradox and complexity in multiple sclerosis and its animal models","author":"Lim","year":"2014","journal-title":"Open Autoimmun J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9&lt;1977::AID-ART345&gt;3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor \u03b1 Antagonism: by what mechanisms could tumor necrosis factor \u03b1 Antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheumat."},{"key":"B21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor necrosis factor \u03b1 and regulatory T cells in oncoimmunology","volume":"9","author":"Salomon","year":"2018","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J Neurol."},{"key":"B25","first-page":"1202","article-title":"Etanercept induced multiple sclerosis and transverse myelitis","volume":"33","author":"N. Al Saieg Luzar","year":"2006","journal-title":"J. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jns.2017.01.023","article-title":"TNF-alpha inhibitor associated myelopathies: a neurological complication in patients with rheumatologic disorders","volume":"373","author":"Barreras","year":"2017","journal-title":"J Neurol Sci."},{"key":"B27","first-page":"1469","article-title":"Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies","volume":"35","author":"Davis","year":"2008","journal-title":"J Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"728371","DOI":"10.1155\/2013\/728371","article-title":"Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis","volume":"2013","author":"Defty","year":"2013","journal-title":"Case Rep Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.08.047","article-title":"Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis","author":"Escalas","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/omcr\/omv015","article-title":"Etanercept-associated myelitis","volume":"2015","author":"Finke","year":"2015","journal-title":"Oxf Med Case Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","article-title":"Inflammatory demyelinating events following treatment with anti-tumor necrosis factor","volume":"45","author":"Fromont","year":"2009","journal-title":"Cytokine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10165-008-0062-z","article-title":"A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy","volume":"18","author":"Kameda","year":"2008","journal-title":"Mod Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msard.2018.08.029","article-title":"NMOSD with anti-MOG antibodies following anti-TNF\u03b1 therapy: a case report","volume":"26","author":"Lommers","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e227584","DOI":"10.1136\/bcr-2018-227584","article-title":"Iatrogenic transverse myelitis in a patient with rheumatoid arthritis","volume":"12","author":"Sarathchandran","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult Scler."},{"key":"B36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10067-013-2419-8","article-title":"Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases","volume":"33","author":"Theibich","year":"2014","journal-title":"Clin Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.meg.0000250589.45984.b4","article-title":"Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease","volume":"19","author":"Vadikolias","year":"2007","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-205779","article-title":"Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis","author":"Yokoyama","year":"2014","journal-title":"BMJ Case Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"Guidelines Working Group of, and Bhpr, BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology."},{"key":"B41","first-page":"4","article-title":"Tumor necrosis factor-alpha antagonist and demielynating diseases","author":"Balsalobre Aznar","year":"2013","journal-title":"J Neurol Neurosci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.10488","article-title":"Successful rechallenge with anti-tumor necrosis factor \u03b1 for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: Comment on the article by Mohan et al","volume":"46","author":"Cisternas","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"The PD-1\u2013PD-L pathway in immunological tolerance","volume":"27","author":"Okazaki","year":"2006","journal-title":"Trends Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by Cd25 Cd4 regulatory T cells constitutively expressing cytotoxic T lymphocyte\u2013associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open."},{"key":"B47","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neurooncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13073-019-0652-8","article-title":"Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach","volume":"11","author":"Khan","year":"2019","journal-title":"Genome Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00415-020-09940-y","article-title":"Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment","volume":"267","author":"Mongay-Ochoa","year":"2020","journal-title":"J Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio JC Ni","year":"2017","journal-title":"Ann Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.2353\/ajpath.2009.081012","article-title":"Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants","volume":"174","author":"Kroner","year":"2009","journal-title":"Am J Pathol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0165-5728(96)00168-3","article-title":"Specific blockade of CTLA-4\/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis","volume":"73","author":"Hurwitz","year":"1997","journal-title":"J Neuroimmunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.msard.2019.101447","article-title":"Neuromyelitis optica spectrum disorder after treatment with pembrolizumab","volume":"37","author":"Shimada","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel Rozeman","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"15542","DOI":"10.18632\/oncotarget.24509","article-title":"Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study","volume":"9","author":"Fujimura","year":"2018","journal-title":"Oncotarget."},{"key":"B71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-018-2258-1","article-title":"Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study","volume":"68","author":"Pistillo","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2177\/jsci.40.95","article-title":"[Varied immuno-related adverse events induced by immune-check point inhibitors - nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6]","volume":"40","author":"Okiyama","year":"2017","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi."},{"key":"B75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","article-title":"CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","article-title":"Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer","volume":"40","author":"Wang","year":"2021","journal-title":"Invest New Drugs."},{"key":"B77","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/1078155215572932","article-title":"Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature","volume":"22","author":"Abdallah","year":"2015","journal-title":"J Oncol Pharm Pract."},{"key":"B78","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s40425-019-0803-x","article-title":"Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature","volume":"7","author":"Carausu","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-018-0471-2","article-title":"Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation","volume":"6","author":"Chang","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00207454.2022.2050907","article-title":"A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications","volume":"7","author":"Esechie","year":"2022","journal-title":"Int J Neurosci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13691-019-00367-5","article-title":"Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature","volume":"8","author":"Kubo","year":"2019","journal-title":"Int Cancer Conf J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J Neurol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12883-022-02576-7","article-title":"Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report","volume":"22","author":"Moodie","year":"2022","journal-title":"BMC Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1159\/000368316","article-title":"Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma","volume":"37","author":"O'Kane","year":"2014","journal-title":"Oncol Res Treat."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B87","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"100324","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalsci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"655283","DOI":"10.3389\/fneur.2021.655283","article-title":"Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab","volume":"12","author":"Charabi","year":"2021","journal-title":"Front Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","article-title":"Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases","volume":"6","author":"Garcia","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1212\/NXI.0000000000000773","article-title":"Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors","volume":"7","author":"Nowosielski","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B92","first-page":"92","article-title":"Hunting the real culprit: a complex case of nivolumab-related myelitis (P42-006)","author":"Poretto","year":"2019","journal-title":"Neurology.."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B94","first-page":"357","article-title":"Checkpoint inhibitor-induced longitudinally extensive transverse myelitis: a report on two cases","volume":"25","author":"Makkawi","year":"2019","journal-title":"Multiple Sclerosis J."},{"key":"B95","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.94.15_supplement.815","article-title":"Case report of recurrent longitudinally extensive holocord transverse myelitis after combination immune checkpoint inhibitor therapy with nivolumab and ipilimumab (815)","volume":"94","author":"Brahmbhatt","year":"2020","journal-title":"Neurology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"8819296","DOI":"10.1155\/2020\/8819296","article-title":"Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review","volume":"2020","author":"Vickers","year":"2020","journal-title":"Case Rep Oncol Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"key":"B98","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Comprehens Cancer Netw."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1080\/10428194.2019.1633635","article-title":"Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymph."},{"key":"B105","doi-asserted-by":"publisher","first-page":"102728","DOI":"10.1016\/j.amsu.2021.102728","article-title":"Radiation induced delayed transverse myelitis and neurological deficit at tertiary care center","volume":"69","author":"Abuzneid","year":"2021","journal-title":"Ann Med Surg."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1177\/1352458519892914","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: a report of two cases","volume":"26","author":"Rotstein","year":"2019","journal-title":"Mult Scler."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"103331","DOI":"10.1016\/j.retram.2021.103331","article-title":"A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma","volume":"70","author":"Beauvais","year":"2022","journal-title":"Curr Res Transl Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.retram.2018.03.003","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","article-title":"Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy","volume":"106","author":"Nair","year":"2020","journal-title":"Haematologica."},{"key":"B112","doi-asserted-by":"publisher","first-page":"120044","DOI":"10.1016\/j.jns.2021.120044","article-title":"Exposure to TNF inhibitors is rare at MOGAD presentation","volume":"432","author":"Redenbaugh","year":"2022","journal-title":"J Neurol Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1003270\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:32:13Z","timestamp":1728081133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1003270\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":113,"alternative-id":["10.3389\/fneur.2022.1003270"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1003270","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"1003270"}}